JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will take part in a fireside chat at the Guggenheim Radiopharmaceuticals Day in New York City on Monday, May 15th, 2023.
| Event: | Guggenheim Radiopharmaceuticals Day |
| Date: | Monday, May 15th, 2023 |
| Time: | 11:20 AM ET |
| Location: | New York, NY |
| Webcast: | Link |
Mr. Levy will also be available for 1x1 investor meetings at the conference. Please reach out to your Guggenheim representative to schedule.
About Alpha Tau Medical, Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Investor Relations Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.57 |
| Daily Change: | 0.04 1.58 |
| Daily Volume: | 4,921 |
| Market Cap: | US$180.160M |
April 02, 2025 March 12, 2025 January 27, 2025 December 18, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
